TICKERNERD
Menu
RANIRANIHealthcare · Biotechnology

RANI Stock Forecast: Rani Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.88
+3.41% on the day

The 5 Wall Street analysts covering Rani Therapeutics Holdings, Inc. hold a median 12-month price target of $6 — +581.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$126.0M
Ticker Nerd rank
64 / 100
Median analyst target
$6.00
Analysts covering
5
Total return, dividends reinvested
1W
+10.6%
1M
+27.4%
YTD
−34.8%
1Y
+60.3%
From 52W high
−69.1%
From 52W low
+92.1%
$0.46
$2.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RANI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rani Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Accruals
76
Revisions
75
Size
74
Issuance
60
Momentum
49
Value
28
Quality
18
Volatility
8

Growth (93): Sales and profits are climbing, and climbing faster than before.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RANI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RANI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26RANIHigh $11.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $5.00Median $6.00High $11.00

The green dot is the last close — the median target sits +581.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026Chardan CapitalInitiatesBuy$6.00
20 May 2026Canaccord GenuityMaintainsBuy—
20 May 2026Canaccord GenuityMaintainsBuy$5.00
1 Apr 2026Canaccord GenuityMaintainsBuy—
27 Mar 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
21 Oct 2025HC Wainwright & Co.AssumesBuy$11
20 Oct 2025Maxim GroupMaintainsBuy—
16 May 2025OppenheimerMaintainsOutperform—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
26 Feb 2025Canaccord GenuityMaintainsBuy—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.MaintainsBuy—
2 Aug 2024OppenheimerInitiatesOutperform—
25 June 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024Maxim GroupInitiatesBuy—
13 June 2024Rodman & RenshawInitiatesBuy—
9 May 2024BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RANI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RANI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Rani Therapeutics Holdings, Inc. (RANI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 85% of US stocks

Price / sales
24.8×

Cheaper than 8% of US stocks

Price / book
3.0×

Cheaper than 35% of US stocks

EV / EBITDA
−2.0×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
16.9%

Higher than 66% of US stocks

Earnings growth (YoY)
893.0%

Higher than 97% of US stocks

Gross margin
—
Operating margin
−516.9%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−172.1%

Higher than 8% of US stocks

Return on assets
−53.0%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RANI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RANIRani Therapeutics Holdings, Inc.$126.0M
64
NAUTNautilus Biotechnology, Inc.$121.3M
55
HURATuHURA Biosciences, Inc.$121.4M
17
GNLXGenelux Corp.$121.6M
19
INOInovio Pharmaceuticals, Inc.$121.9M
44
NTHINeOnc Technologies Holdings, Inc.$116.5M
20
GUTSFractyl Health, Inc.$123.7M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rani Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RANI news & analysis

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Benzinga · 18 Aug 2026neutral

Top Wall Street analysts changed their outlooks on several names, with the article highlighting five analyst coverage initiations for Tuesday, including a Definium Therapeutics analyst beginning coverage on a bullish note. The item directs readers to a full analyst ratings page for all upgrades, downgrades, and initiations.

Why it matters — A RANI watcher would care because analyst coverage initiations and rating changes can draw investor attention and affect market sentiment toward stocks generally and within the biotech/therapeutics space.

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

MarketBeat · 16 Aug 2026positive

Rani Therapeutics outlined a strategy to expand the use of its RaniPill oral biologic-delivery platform through technology partnerships, selectively licensed product programs, and investments in manufacturing capacity.

Why it matters — The strategy signals how Rani plans to broaden its oral biologic platform beyond its current focus into areas such as obesity and immunology.

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

GlobeNewsWire · 13 Aug 2026positive

Rani Therapeutics reported its second quarter 2026 financial results and corporate update. The company advanced RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort and positive initial Phase 1a data showing oral bioavailability exceeding 150% relative to matched subcutaneous dosing. It also completed a $20 million registered direct offering, expanded its obesity pipeline through a collaboration with PegBio, and appointed Nicholas Maestas as CFO and Michelle Gilson to the Board of Directors.

Why it matters — A RANI watcher would care because the positive initial Phase 1a data for RT-114, pipeline expansion via the PegBio collaboration, and strengthened leadership signal continued progress on the company's oral-delivery platform.

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 10 Aug 2026neutral

Rani Therapeutics announced that its management team will participate in the Canaccord Genuity 46th Annual Growth Conference, with details of the event provided by the company. The clinical-stage biotherapeutics company made the announcement on August 10, 2026.

Why it matters — RANI watchers would care because conference participation provides a forum for the company's management to present its oral-delivery biologics pipeline to investors and analysts.

FAQ

Frequently asked questions about RANI stock

What is the RANI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Rani Therapeutics Holdings, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RANI stock a buy right now?

Of the 5 analysts covering Rani Therapeutics Holdings, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rani Therapeutics Holdings, Inc. 64 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RANI?

As at 22 Aug 2026, Rani Therapeutics Holdings, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will RANI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +581.8% from the last close, and Ticker Nerd's factor model ranks Rani Therapeutics Holdings, Inc. 64 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RANI stock forecast for 2030?

No analyst covering Rani Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $11 over the next 12 months.

How has RANI stock performed over the past year?

Rani Therapeutics Holdings, Inc. returned +60.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rani Therapeutics Holdings, Inc. do?

Rani Therapeutics Holdings Inc. is a pioneering entity in the biopharmaceutical field, dedicated to transforming the delivery of biologics and other macromolecules.

What is the latest news on RANI?

The most recent item we track (Benzinga, 18 Aug 2026): "This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday". Top Wall Street analysts changed their outlooks on several names, with the article highlighting five analyst coverage initiations for Tuesday, including a Definium Therapeutics analyst beginning coverage on a bullish note. The item directs readers to a full analyst ratings page for all upgrades, downgrades, and initiations.

Company

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings Inc. is a pioneering entity in the biopharmaceutical field, dedicated to transforming the delivery of biologics and other macromolecules. The company endeavors to address challenges associated with the oral administration of biologic drugs, which are typically delivered through injections, by developing the RaniPill capsule. This innovative technology is designed to enable the oral delivery of these complex drugs, significantly impacting how treatments can be administered for chronic diseases such as diabetes, rheumatoid arthritis, and other autoimmune disorders. Operating at the intersection of pharmaceuticals and cutting-edge medical technology, Rani Therapeutics stands as a disruptive force within the healthcare sector, aiming to enhance patient compliance and expand market access for critical therapies. Established to advance healthcare delivery, the company's work holds potential significance for pharmaceutical manufacturers, healthcare providers, and patients, offering a unique solution to a long-standing challenge in the medical industry. As Rani Therapeutics Holdings Inc. continues its pursuit of novel drug delivery methods, it remains an important player in the biopharmaceutical innovation landscape.

CEO Mr. Talat Imran · 69 employees · United States · https://www.ranitherapeutics.com